Calendario›REGN›REGN9533
REGN9533
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults
Ensayo de REGENERON PHARMACEUTICALS, INC. en Voluntarios sanos.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 72
- Centros
- 1
- Fin del objetivo primario
- ene 2026
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en mar 2025.
Qué mide
Incidence of Treatment Emergent Adverse Events (TEAEs) (del registro, en inglés) (hasta 100 dias)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe aim of this clinical trial is to see how safe and tolerable the clinical trial drug (REGN9533) is in healthy participants. This is the first time that REGN9533 will be given to humans. After the clinical trial drug has been tested in healthy participants, future studies with REGN9533 will focus on participants with thromboembolic (blocking of blood vessels) diseases which include blood clots. REGN9533 is a drug that is only used in clinical studies. The clinical trial is looking at: * The side effects REGN9533 might cause * How much REGN9533 is in the blood at different times * How the body reacts to REGN9533 * If the body makes antibodies to REGN9533 (unwanted immune response, which may cause REGN9533 to not work as well) * What is the best dose of REGN9533
Más ensayos de REGN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| cemiplimab | Fase 2 | En marcha, sin reclutar | mar 2025 (real) |
| Pozelimab + Cemdisiran · NIMBLE | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Garetosmab · OPTIMA | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Aflibercept 8 mg · ELARA | Fase 3 | En marcha, sin reclutar | ago 2025 (real) |
| Dupilumab · ENGAGE | Fase 2 | En marcha, sin reclutar | feb 2026 (real) |
| Fianlimab | Fase 3 | En marcha, sin reclutar | mar 2026 (real) |
Todos los de REGN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06665828), actualizada en feb 2026.